This subset ultimately acts as a regulator of LCRC aggressiveness, promoting tumor invasion through TGF-β signaling, upregulation of pro-tumor genes (RAMP1, MYLK, MYH11) and activation of muscle-invasive pathways. The gene discussed is MYLK; the disease is neoplasm.